Journals / Türk Biyokimya Dergisi / 2008 / Cilt: 33 - Sayı: 3

Resveratrol: A clinician point of view]

Resveratrole klinisyen bakışı

Pages
122–125
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Before getting these results, resveratrol containing drugs or foods should not be recommended as part of a medical treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Experimental data suggest that resveratrol, an antioxidant molecule, has beneficial effects on cardiovascular system.
📊
Key Findings & Data:Evidence-based medicine (EBM) aims to apply evidence gained from the hard end-point placebo controlled randomized clinical trials to certain parts of medical practice.There have been many molecules, including vitamin E, which were shown to have positive effects in experimental models (that is further supported by observational clinical studies) but failed to show any benefit in hard end-point randomized clinical trials.
💡
Conclusion & Impact:Before getting these results, resveratrol containing drugs or foods should not be recommended as part of a medical treatment.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Experimental data suggest that resveratrol, an antioxidant molecule, has beneficial effects on cardiovascular system. Evidence-based medicine (EBM) aims to apply evidence gained from the hard end-point placebo controlled randomized clinical trials to certain parts of medical practice.There have been many molecules, including vitamin E, which were shown to have positive effects in experimental models (that is further supported by observational clinical studies) but failed to show any benefit in hard end-point randomized clinical trials. Despite its beneficial cardiovascular effects, resveratrol is commonly referred to as a ‘‘dirty’’ molecule in the pharmaceutical industry, meaning that it seems to interact with many different proteins, including cyclooxygenases, ribonucleotide reductase and DNA polymerases. Thus, its activity cannot be resumed in a unique mechanism of action but likely results from various complementary actions of different biochemical pathways. Randomized clinical trials are needed to test whether positive effects of resveratrol obtained from experimental models would lead to any improvement in cardiovascular outcome. Before getting these results, resveratrol containing drugs or foods should not be recommended as part of a medical treatment.

Özet

Resveratrolün oksidatif stresi azalttığı deneysel modellerde gösterilmiştir. Oksidatif stresin azaltılmasının kalp damar hastalığı gelişimini önlemede faydalı olabileceği bilimsel temellere dayalı bir görüştür. Ancak kanıta dayalı tedavi yaklaşımı bir molekülün deneysel modellerde başarılı olmasını (bu veriler gözlemsel klinik çalışmalarda doğrulansa bile) bu molekülün rutin klinik kullanımı için yeterli görmemektedir. Kanıta dayalı tedavi yaklaşımının felsefesi, faydalı olduğu düşünülen bir molekülün, insanlarda yaygın olarak kullanılmaya başlanmadan önce, gerçekten faydalı olup olmadığının sert sonlanım noktalı, randomize klinik çalışmalarla test edilmesi gerekliliğidir. Deneysel ve gözlemsel klinik çalışmalar sonucunda kalp damar hastalığından korunmada büyük umut vaat eden E vitamini büyük randomize klinik çalışmalarla test edildiğinde hiçbir faydası gösterilememiş, hatta kalp yetersizliği gelişimini artırabileceği yönünde sonuçlara ulaşılmıştır. Kardiyoloji literatüründe potansiyel faydalarına karşın randomize klinik çalışmalarla plasebodan üstün çıkmayan tedavi yaklaşımlarının sayısı azımsanmayacak düzeydedir. Resveratrol potansiyel faydalarına karşın farmasötik endüstride kirli molekül (dirty molecule) olarak adlandırılmaktadır. Bunun nedeni siklooksijenaz, ribonükleotid redüktaz ve DNA polimerazlar gibi çok farklı proteinlerle etkileşim içinde bulunuyor olmasıdır. Bu da resveratrol hakkında bilmediklerimizin, bildiklerimizden fazla olduğunu düşündürmektedir. Resveratrolün potansiyel olumlu etkilerinin kalp krizini önleme, sağ kalımı uzatma gibi klinik faydaya dönüşüp dönüşmeyeceğini anlamanın yolu plasebo kontrollü randomize klinik çalışmaların planlanmasıdır. Bu tip çalışmalar olumlu sonuç vermedikçe resveratrol içeren ilaç veya gıdaların, şifa amaçlı kullanımını önermek yanlış olacaktır.

🔖

Cite This Article

GÜLEÇ, S. (2022). Resveratrol: A clinician point of view]. Türk Biyokimya Dergisi, Cilt: 33 - Sayı: 3, 122–125. https://ajindex.com/articles/621352

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. (1992) Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 94:153-159
  2. Steiner M. (1991) Influence of vitamin E on platelet function in humans. J Am Coll Nutr. 10:466-473
  3. Skyrme-Jones RA, O’Brien RC, Berry KL, Meredith IT. (2000) Vitamin E supplementation improves endothelial function in type 1 diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol. 36:94-100
  4. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. (1996) Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 334:1156-1162
  5. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. (1993) Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 328:1450-1456
  6. The Heart Outcomes Prevention Evaluation Study Investigators. (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 342:154-160
  7. Heart Protection Collaborative Group. (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 360:23-33
  8. Marchioli R, Levantesi G, Macchia A, Marfisi RM, Nicolosi GL, Tavazzi L, Tognoni G, Valagussa F; GISSI-Prevenzione Investigators. (2006) Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial. J Cardiovasc Med. 5:347-50
  9. Moat SJ, McDowell IF. (2005) Homocysteine and endothelial function in human studies. Semin Vasc Med. 2:172-82
  10. Wilson KM, Lentz SR. (2005) Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Semin Vasc Med. 2:163-71 [11] Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 291:565-75
  11. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 354:1578-88
  12. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. (2006) H